

Journal Pre-proof

Treatment options for COVID-19: the reality and challenges

Shio-Shin Jean, Ping-Ing Lee, Po-Ren Hsueh

PII: S1684-1182(20)30094-3

DOI: <https://doi.org/10.1016/j.jmii.2020.03.034>

Reference: JMII 1222

To appear in: *Journal of Microbiology, Immunology and Infection*

Received Date: 30 March 2020

Accepted Date: 31 March 2020

Please cite this article as: Jean S-S, Lee P-I, Hsueh P-R, Treatment options for COVID-19: the reality and challenges, *Journal of Microbiology, Immunology and Infection*, <https://doi.org/10.1016/j.jmii.2020.03.034>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Copyright © 2020, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.



Treatment options for COVID-19: the reality and challenges

Shio-Shin Jean^{a,b}, Ping-Ing Lee^c, Po-Ren Hsueh^{d,e,*}

^aDepartment of Emergency, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan;

^bDepartment of Emergency Medicine, Department of Emergency and Critical Care Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan;

^cDepartment of Pediatrics, National Taiwan University Children's Hospital and National Taiwan University College of Medicine, Taipei, Taiwan;

^dDepartment of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan;

^eDepartment of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

*Corresponding author. Departments of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, No. 7 Chung-Shan South Road, Taipei, 100, Taiwan.

E-mail address: hsporen@ntu.edu.tw (P.-R. Hsueh).

Abstract An outbreak related to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China in December 2019. An extremely high potential for dissemination resulted in the global coronavirus disease 2019 (COVID-19) pandemic in 2020. Despite the worsening trends of COVID-19, no drugs are validated to have significant efficacy in clinical treatment of COVID-19 patients in large-scale studies. Remdesivir is considered the most promising antiviral agent; it works by inhibiting the activity of RNA-dependent RNA polymerase (RdRp). A large-scale study investigating the clinical efficacy of remdesivir (200 mg on day 1, followed by 100 mg once daily) is on-going. The other excellent anti-influenza RdRp inhibitor favipiravir is also being clinically evaluated for its efficacy in COVID-19 patients. The protease inhibitor lopinavir/ritonavir (LPV/RTV) alone is not shown to provide better antiviral efficacy than standard care. However, the regimen of LPV/RTV plus ribavirin was shown to be effective against SARS-CoV *in vitro*. Another promising alternative is hydroxychloroquine (200 mg thrice daily) plus azithromycin (500 mg on day 1, followed by 250 mg once daily on day 2-5), which showed excellent clinical efficacy on Chinese COVID-19 patients and anti-SARS-CoV-2 potency *in vitro*. The roles of teicoplanin (which inhibits the viral genome exposure in cytoplasm)

41 and monoclonal and polyclonal antibodies in the treatment of SARS-CoV-2 are
42 under investigation. Avoiding the prescription of non-steroidal
43 anti-inflammatory drugs, angiotensin converting enzyme inhibitors, or
44 angiotensin II type I receptor blockers is advised for COVID-19 patients.

45

46 **KEYWORDS:** Severe acute respiratory syndrome coronavirus 2
47 (SARS-CoV-2), coronavirus disease 2019 (COVID-19), remdesivir,
48 hydroxychloroquine, non-steroidal anti-inflammatory drugs, angiotensin
49 converting enzyme inhibitors.

50

Introduction

In December 2019, Wuhan city (the capital city of Hubei province, China) experienced a major outbreak caused by a novel coronavirus. This outbreak was found to be caused by a novel virus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).¹⁻³ Numerous clinical SARS-Co-2 cases have been reported and were distributed among more than half of the countries of the world during a less than 6-month period (data till March 28, 2020).⁴⁻⁷ The lower respiratory tract is the primary target of the SARS-CoV-2 infection. It is noteworthy that adults with coronavirus disease 2019 (COVID-19) often present with a profound decrease in both CD4⁺ and CD8⁺ T-cell subsets at the early stage of this disease.^{1,8} Subsequently, patients suffered acute respiratory distress syndrome for about 7-10 days after the onset of COVID-19 due to rapid viral replication, a stormy increase of pro-inflammatory cytokines as well as chemokine response, and inflammatory cell infiltrates.^{8,9} Nevertheless, contrary to the SARS cases in 2003,¹⁰ some SARS-CoV-2 infection patients did not have the prodromal symptoms of upper respiratory tract infection (e.g., cough, sore throat, rhinorrhea), viremia-associated laboratory abnormalities (e.g., leukopenia, lymphopenia, anemia, elevation of liver enzymes and lactic dehydrogenase), or initial evidence of diagnostic

70 chest roentgenographic abnormalities.^{6,11} In addition, uncertain seasonality
71 and the incubation period of SARS-CoV-2 infection oscillating between 2 and
72 14 days make it remarkably difficult to achieve early diagnosis and initiate
73 treatment on time.^{5,9} Previous studies demonstrated that human
74 coronavirus-NL63 (HCoV-NL63) is able to use angiotensin-converting
75 enzyme-2 (ACE2) as a cell receptor in humans.^{5,12} Although children are
76 considered to be significantly less susceptible to HCoV-NL63 infection and
77 have milder disease severity than adults,^{1,5,8,13} the SARS-CoV-2 infection has
78 become a public health menace to people around the world presently because
79 of high transmission potential and unpredictability of disease progression.¹⁴ In
80 order to contain SARS-CoV-2 spread among community residents, stringent
81 infection control measures were implemented by the Centers for Disease
82 Control (CDC) and Prevention of Taiwan since February, 2020. According to
83 an investigation by To *et al.* (2020),¹⁵ patients with SARS-CoV infection had
84 the highest viral load (measured from posterior oropharyngeal saliva samples)
85 close to when they presented. To *et al.* concluded that since viral load had
86 already peaked around the time of hospital admissions, early use of potent
87 antiviral agents might be beneficial in controlling COVID-19 severity.¹⁵
88 However, standard treatment against COVID-19 is presently lacking. Herein,

the roles of several drugs including antiviral agents, some antibiotics and anti-inflammatory agents have been reviewed to explore their efficacy in combating the SARS-CoV-2 (data until March 28, 2020).

RNA-dependent RNA polymerase inhibitors

Remdesivir

Among several potential drugs tested for efficacy in treatment of SARS-CoV-2 infection,¹⁶ remdesivir (GS-5734; Gilead Sciences Inc., Foster City, CA, USA) is shown to be the most promising and hopeful anti-viral therapeutic. It works by targeting viral RNA-dependent RNA polymerase (RdRp) while evading proofreading by viral exoribonuclease,¹⁷ resulting in premature termination of viral RNA transcription. Unlike other nucleotide analogues, remdesivir is a phosphoramidate prodrug with broad-spectrum activity against many virus families, including *Filoviridae*, *Paramyxoviridae*, *Pneumoviridae*, and *Orthocoronavirinae* (such as pathogenic SARS-CoV and Middle East respiratory syndrome coronavirus [MERS-CoV]).^{18,19}

Information regarding the pharmacokinetics of remdesivir in humans is not available. Nevertheless, valuable data from rhesus monkeys revealed an intravenous 10 mg/kg dose of remdesivir could lead to a remarkably high

intracellular concentration ($>10\ \mu\text{M}$) of active triphosphate form in peripheral blood mononuclear cells for at least 24 h,²⁰ supporting its clinical potential in the treatment of human SARS-CoV-2 infection. Additionally, data on the safety of remdesivir in humans are available online.²¹ The first COVID-19 patient in the USA was successfully treated with remdesivir for the progression of pneumonia on day 7 of hospitalization in January, 2020.⁴ Phase 3 human trials (ClinicalTrials.gov Identifier: NCT04292899 and NCT04292730, for severe and moderate adult SARS-CoV-2 cases, respectively) have been initiated to evaluate its efficacy in patients with SARS-CoV-2 infection since March, 2020. Patients received 200 mg on day 1, followed by 100 mg once daily from day 2. Despite its encouragingly high *in vitro* potency against SARS-CoV-2 and the clinical success in treatment of COVID-19,^{4,18} uncertainties about adverse effects (e.g., nausea, vomiting, rectal hemorrhage, and hepatic toxicity) and clinical efficacy of remdesivir have been reported recently.²²

In a mouse model investigating the pathogenesis of SARS-CoV, prophylactic and early therapeutic post-exposure administration of remdesivir were shown to produce a significant reduction in pulmonary viral load (i.e., >2 orders of magnitude on day 2-5 post-infection), mitigate disease progression and prominently improve respiration function.¹⁸ Furthermore, Brown *et al.*

observed that remdesivir displayed half-maximum effective concentrations (EC₅₀s) of 0.069 μ M for SARS-CoV, and 0.074 μ M for MERS-CoV in tissue culture models.²³ In addition, tissue culture experiments also revealed that many highly divergent CoV including the endemic human CoVs (HCoV-OC43, HCoV-229E) and zoonotic CoV are effectively inhibited by remdesivir within the submicromolar EC₅₀s.^{23,24} Of note, the similar efficacy of prophylactic and therapeutic remdesivir treatment (24 h prior to inoculation, and 12 h post-inoculation, respectively) was also seen in the context of a non-human primate (rhesus macaque) model of MERS-CoV infection.²⁵ Although two amino acid substitutions (F476L, V553L) in the non-structural protein 12 polymerase were demonstrated to confer low-level resistance to remdesivir, this resistance also impaired the fitness of the tested CoVs and is actually difficult to select.¹⁷

Favipiravir

The other RdRp inhibitor favipiravir (Fujifilm Toyama Chemical Co. Ltd, Tokyo, Japan) is known to be active *in vitro* against oseltamivir-resistant influenza A, B, and C viruses.²⁶ After being converted into an active phosphoribosylated form, favipiravir is easily recognized as a substrate of viral RNA polymerase in many

RNA viruses.²⁷ The recommended dose of favipiravir against influenza virus is 1600 mg administered orally twice daily on day 1, then 600 mg orally twice daily on day 2-5, and 600 mg once on day 6. Recently, preliminary results of clinical studies have shown favipiravir to have promising potency in treatment of Chinese patients with SARS-CoV-2 infection.²⁸ Favipiravir was approved for the treatment of COVID-19 in China in March, 2020. In addition, patients with COVID-19 infection are being recruited for randomized trials to evaluate the efficacy of favipiravir plus interferon- α (ChiCTR2000029600) and favipiravir plus baloxavir marboxil (ChiCTR2000029544).

Ribavirin

Ribavirin (Bausch Health Companies Inc., Bridgewater, NJ, USA) is a guanosine analogue antiviral drug that has been used to treat several viral infections, including hepatitis C virus, respiratory syncytial virus (RSV), and some viral hemorrhagic fevers. The *in vitro* antiviral activity of ribavirin against SARS-CoV was estimated to be at a concentration of 50 $\mu\text{g/mL}$.²⁹ However, it has the undesirable adverse effect of reducing hemoglobin, which is harmful for patients in respiratory distress.¹⁹

Interferons

Treatment with interferon β (IFNb)-1b (Bayer Pharmaceutical Co., Leverkusen, Germany), an immunomodulatory agent, was shown to result in clinical improvement among MERS-CoV-infected common marmosets, but the benefits of IFn β -1b for SARS patients remains uncertain.^{29,30}

Protease inhibitors

Lopinavir/ritonavir

Protease inhibitors (PIs) are important agents in the contemporary treatment of patients with chronic human immunodeficiency virus (HIV) infection. In the Orthocoronavirinae family, the targets of PIs are papain-like protease and 3C-like protease.³⁰ The antiviral activity of lopinavir (LPV; Abbott Laboratories, Lake Bluff, Illinois, US) against MERS-CoV in a tissue culture model is controversial, despite a good effect in mitigating disease progression in MERS-CoV-infected marmosets.²⁹ Of note, Sheahan *et al.* (2020) compared the efficacy of prophylactic remdesivir (25 mg/kg twice a day, administered 1 day prior to infection) as well as therapeutic remdesivir with that of LPV/ritonavir (RTV, used to prolong the LPV's half-life)-IFN β combination therapy in a humanized transgenic mouse MERS-CoV infection model. They

observed the efficacy of remdesivir was superior to that of LPV/RTV-IFN β against MERS-CoV in terms of viral load reduction and improvement in extent of pathologic change in lung tissue.³¹ In addition to gastrointestinal adverse effects (nausea, vomiting, and diarrhea) induced by LPV/RTV, it is noteworthy that LPV/RTV treatment alone (400/100 mg administered orally twice daily for 14 days; Chinese Clinical Trial Register number, ChiCTR2000029308) failed to provide benefits compared to standard care alone. Median time to clinical improvement in both cases was 16 days (hazard ratio [HR], 1.31; 95% confidence interval [CI], 0.95 to 1.85; $P=0.09$) and there was no difference in the reduction of viral RNA loading for severe SARS-CoV-2 patients.³²

Despite discouraging results, it is intriguing that a slightly lower number of deaths was observed in the group receiving LPV/RTV in the late stage of SARS-CoV-2 infection compared with the standard-care group. Moreover, Baden and Ruben (2020) and Sheahan *et al.* (2020) suggested that the LPV/RTV concentration necessary to inhibit pulmonary SARS-CoV-2 replication might be higher than the serum level.^{31,33} A randomized, controlled open-label trial was launched in China to evaluate the efficacy of LPV/RTV (200/50 mg twice a day) among hospitalized patients with SARS-CoV-2 infections in 2020 (ChiCTR2000029308). The role of darunavir (Janssen

Pharmaceutica, Beerse, Belgium), also a promising PI against SARS-CoV-2 *in vitro*, needs to be further evaluated.³⁴ Ribavirin in combination with interferon- α 2b was shown to be active against MERS-CoV in a rhesus macaque model.³⁵ Additionally, the regimen of LPV/RTV plus ribavirin was shown to be effective against SARS-CoV in patients and in tissue culture.³⁶

Chloroquine, hydroxychloroquine, and azithromycin

Chloroquine is active against malaria as well as autoimmune diseases (such as rheumatoid arthritis [RA], lupus erythematosus). It was recently reported as a potential broad-spectrum antiviral drug for treatment of viruses such as influenza H₅N₁ in an animal model.³⁷ Chloroquine was shown to increase endosomal pH, which prevents virus/cell fusion. It also interferes with the glycosylation of cellular receptors of SARS-CoV.^{38,39} Although the *in vitro* data of chloroquine is promising (EC₉₀ of 6.90 μ M, using Vero E6 cells infected by SARS-CoV-2), an extensive prescription of chloroquine in clinical treatment of SARS-CoV-2 is a completely off-label use. It is not recommended in light of safety concerns (adverse effects on the hematologic, hepatic and renal systems, QTc prolongation with ventricular dysrhythmia) and will likely result in a major shortage of anti-malarial armamentaria.⁴⁰

Hydroxychloroquine is also proposed to control the cytokine storm that occurs in critically ill late phase SARS-CoV-2 infected patients.⁴¹ Hydroxychloroquine is significantly more potent than chloroquine *in vitro* (EC₅₀ values: 0.72 and 5.47 μ M, respectively) and has lower potential for drug-drug interactions than chloroquine. Pharmacokinetic models demonstrate that hydroxychloroquine sulfate is significant superior (5 days in advance) to chloroquine phosphate in inhibiting SARS-CoV-2 *in vitro*.⁴¹ The Taiwan CDC declared hydroxychloroquine as an important anti-SARS-CoV-2 agent on 26 March, 2020. Of note, patients with retinopathy, deficiency of glucose-6-phosphatase, QTc prolongation in electrocardiograms, history of allergy to hydroxychloroquine or who are pregnant or breastfeeding are contraindicated for receiving hydroxychloroquine therapy.⁴²

Azithromycin (Pfizer Inc., Manhattan, New York City, NY, USA) was shown to be active *in vitro* against Ebola viruses.⁴³ Furthermore, azithromycin is thought to have good potential in preventing severe respiratory tract infections among pre-school children when it is administrated to patients suffering viral infection.⁴⁴ According to one recent study, azithromycin (500 mg on day 1, followed by 250 mg per day on day 2-5) was shown to significantly reinforce the efficacy of hydroxychloroquine (200 mg three times per day for 10 days) in

the treatment of 20 patients with severe COVID-19. Mean serum hydroxychloroquine concentration was 0.46 ± 0.20 $\mu\text{g/mL}$. The good clinical outcome among these COVID-19 patients was thought to be due to the excellent efficiency of virus elimination after administration of this combination therapy.⁴² Consequently, the regimen of hydroxychloroquine in combination with azithromycin might be a promising alternative to remdesivir in the treatment of patients with SARS-CoV-2 infection in the future. Nevertheless, the possibility of complicated QTc prolongation should be concerned.

Teicoplanin and other glycopeptides

The other antibiotics worth mentioning in this review are glycopeptides. Teicoplanin (Sanofi Pharmaceuticals, Paris, France) was demonstrated to potently prevent the entry of Ebola envelope pseudotyped viruses into the cytoplasm, and also has an inhibitory effect on transcription- as well as replication-competent virus-like particles in the low micromolar range (IC_{50} , 330 nM).⁴⁵ Moreover, teicoplanin is able to block the MERS and SARS envelope pseudotyped viruses as well.⁴⁵ Mechanistic investigations revealed that teicoplanin specifically inhibits the activities of host cell's cathepsin L and cathepsin B, which are responsible for cleaving the viral glycoprotein allowing

exposure of the receptor-binding domain of its core genome and subsequent release into the cytoplasm of host cells.^{46,47} Thus, teicoplanin blocks Ebola virus entry in the late endosomal pathway. These studies indicate the potential role of teicoplanin and its derivatives (dalbavancin, oritavancin, and telavancin) as novel inhibitors of cathepsin L-dependent viruses.

A brief summary of the mechanism of action and targets of potential antimicrobial agents against SARS-CoV-2 is shown in **Table 1**.

Monoclonal or polyclonal antibodies and other therapies

Monoclonal or polyclonal antibodies have been suggested as prophylactic and therapeutic tools (targeting hemagglutinin binding) against some viral infections, such as influenza.⁴⁸ Current efforts in developing monoclonal and polyclonal antibodies against coronaviruses mainly target MERS-CoV.¹⁸ For example, a human polyclonal antibody SAB-301 (50 mg/kg) that was generated in transchromosomal cattle was observed to be well tolerated and safe in healthy participants of a phase 1 clinical trial.⁴⁹ However, Cockrell *et al.* (2016) observed that immune-based therapy with human monoclonal antibodies only provided protection against early stage disease caused by MERS-CoV in mouse models.^{19,50}

Numerous *in vitro* studies have shown that the spike protein of SARS-CoV is important in mediating viral entry into target cells. Furthermore, the cleavage and subsequent activation of the SARS-CoV spike protein by a protease of the host cell is absolutely essential for infectious viral entry.⁵¹ Type II transmembrane serine protease TMPRSS2 was suggested to be an important host protease that cleaves and activates the SARS-CoV spike protein in cell cultures, and was thus explored as a potential antiviral agent.¹⁸ In the past decade, the serine protease inhibitor camostat mesylate was shown to inhibit the enzymatic activity of TMPRSS2.⁵² Additionally, the cysteine PI K11777 showed promising potency in inhibiting MERS-CoV and SARS-CoV replication within the submicromolar range.⁵³

Use of stem cells against COVID-19 has been under evaluation in China recently. Additionally, tocilizumab (Roche Pharmaceuticals, Basel, Switzerland) is a monoclonal antibody that is used in the treatment of RA exacerbation. It was designed to inhibit the binding of interleukin-6 to its receptors, thus alleviating cytokine release syndrome. Currently, it is also being investigated for treatment of COVID-19.⁵⁴

Convalescent plasma

298 Convalescent plasma has also been used as a last resort to improve the
299 survival rate of patients with various viral infections, such as SARS, H₅N₁ avian
300 influenza, pandemic 2009 influenza A H₁N₁ (H₁N₁ pdm09), and severe Ebola
301 virus infection.^{55,56} One possible explanation for the efficacy of convalescent
302 plasma therapy is that the immunoglobulin antibodies in the plasma of patients
303 recovering from viral infection might suppress viremia. Shen *et al.* (2020)
304 reported on five critically ill patients with laboratory-confirmed COVID-19 and
305 acute respiratory distress syndrome (ARDS) who received transfusion with
306 convalescent plasma with a SARS-CoV-2-specific antibody (binding titer
307 >1:1000 and neutralization titer >40). The convalescent plasma was obtained
308 from 5 patients who recovered from COVID-19 and it was administered to the
309 five enrolled patients between 10 and 22 days after admission. Antiviral agents
310 and methylprednisolone were also administered. Following plasma
311 transfusions, improvements in clinical condition were observed, including
312 normalization of body temperature within 3 days (in 4/5 patients), decrease in
313 Sequential Organ Failure Assessment score, rise in PaO₂/FiO₂, resolution of
314 ARDS (4 patients at 12 days after transfusion), a success of weaning from
315 mechanical ventilation (3 patients within 2 weeks of treatment), and decline in
316 viral loads (became negative within 12 days) and increase in SARS-CoV-2–

specific ELISA and neutralizing antibody titers. Of the 5 patients, 3 were discharged from the hospital (lengths of stay: 53, 51, and 55 days), while 2 were in stable condition at 37 days after transfusions.⁵⁶ The authors concluded that use of convalescent plasma transfusion is beneficial among patients infected with SARS-CoV-2, even though the sample number in this study is small.⁵⁶

Herbal medications

Based on the historical records and anecdotal evidence of SARS and H₁N₁ pdm09 prevention, Chinese herbal drugs were also considered as an alternative approach for prevention of COVID-19 in high-risk populations. However, clinical evidence for these treatments in the prevention of this emerging viral infection is lacking.^{57,58} During the COVID-19 outbreak in China, some traditional Chinese medicine was widely used, and the six most commonly used herbal medicines were *Astragali Radix* (Huangqi), *Glycyrrhizae Radix Et Rhizoma* (Gancao), *Saposhnikoviae Radix* (Fangfeng), *Atractylodis Macrocephalae Rhizoma* (Baizhu), *Lonicerae Japonicae Flos* and *Fructus forsythia* (Lianqiao). However, rigorous clinical trials on large populations should be conducted to confirm the potential preventive effect of

336 Chinese medicine.^{57,58}

337

338 **Antimicrobial agents for potential co-infection**

339 The prevalence of co-infection varied among COVID-19 patients, ranging from
340 0% to 50% among non-survivors. Reported co-pathogens included bacteria,
341 such as *Mycoplasma pneumoniae*, *Candida* species, and viruses (influenza,
342 rhinovirus, coronavirus, and HIV). Influenza A virus was the commonest
343 co-infective virus.⁵⁹ Co-administration of anti-influenza agents and
344 anti-bacterial agents in patients with COVID-19 pneumonia was common.⁵⁹
345 Consequently, a cautious prescription of effective antibiotic(s) covering
346 *Staphylococcus aureus* (including methicillin-resistant *S. aureus*),
347 multidrug-resistant *Streptococcus pneumoniae*, *Klebsiella pneumoniae*, and
348 *Pseudomonas aeruginosa* as well as *Acinetobacter baumannii* species for
349 patients undergoing long hospitalization (> 6 days) is advised.^{60,61}

350

351 **Other considerations and precautions regarding concomitant** 352 **medication**

353 Based on the research of Yang *et al.* (2020),⁶² the most distinctive
354 comorbidities among the non-survivors of COVID-19 in intensive care units

were cerebrovascular disease and diabetes. Similar findings were also observed by Guan *et al.* (2020);⁶³ these patients were usually treated with ACE inhibitors or angiotensin II type I receptor blockers (ARB). As mentioned above,^{5,12} SARS-CoV-2 and SARS-CoV can bind to their target cells through ACE2 receptors expressed by the epithelial cells of lung, intestine and kidney.⁶⁴ Consequently, careful administration of an ACE inhibitor or ARB for patients with SARS-CoV infection in the absence of ARDS is advised.

Additionally, despite conflicting advice from the US Food and Drug Administration,⁶⁵ the use of non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, was thought to be likely to result in an induction of increased ACE2 receptors.⁶⁶ For critically ill adults with COVID-19 who develop fever, acetaminophen might be a better choice for temperature control than NSAIDs.⁶⁷ Of note, according to a study by Wu *et al.* (2020), treatment of COVID-19 patients with methylprednisolone was shown to decrease the case-fatality risk (HR, 0.38; 95% CI, 0.20-0.72).⁶⁸ However, the administered dose of methylprednisolone is not specified in that investigation. Despite a lack of supporting evidence, some critical care experts advocate the use of low-dose corticosteroid therapy in adults with COVID-19 and refractory shock (e.g., intravenous hydrocortisone 200 mg per day, as a “shock-reversal”

374 strategy).⁶⁸

375 Moreover, a recent report by Tang *et al.* (2020) demonstrated that
376 anticoagulant therapy with heparin (mainly with low molecular weight heparin)
377 was associated with better prognosis in severe COVID-19 patients. The
378 28-day mortality of heparin users was lower than that of non-users among
379 patients with sepsis-induced coagulopathy scores ≥ 4 (40.0% vs. 64.2%,
380 $P=0.029$), or D-dimer > 6 -fold the upper limit of normal (32.8% vs. 52.4%,
381 $P=0.017$).⁶⁹

382 Finally, high ACE2 activity is associated with reduced severity of ARDS
383 among patients with lower respiratory tract infection caused by RSV.⁷⁰ Fedson
384 *et al.* (2016, 2020) observed that statins target the host response to infection
385 (endothelial dysfunction) rather than the virus itself, and suggested that
386 combination therapy with ARB and statins might accelerate a return to
387 homeostasis, allowing patients to recover on their own.^{71,72}

388

389 **Conclusions**

390 In summary, we are facing a terrible virus with greater infectivity than the
391 SARS-CoV pandemic of 2003. There is presently no vaccine or documented
392 specific anti-SARS-CoV-2 drug regimen to treat critically ill patients. Most of

the potential drugs for treatment of COVID-19 are being investigated for safety and efficacy against SARS-CoV-2. Remdesivir is the most promising agent. In addition, favipiravir and combination therapy with hydroxychloroquine plus azithromycin appear to be acceptable alternatives for treatment of COVID-19 patients. For patients with SARS-CoV-2 infection, ACE inhibitor and ARB need to be prescribed with caution. Compared with NSAIDs, acetaminophen might be a safer agent for treating fever in COVID-19 patients. Finally, low-dose steroid (hydrocortisone) might be prescribed for treatment of refractory shock in patients with COVID-19.

Statement of interests

The authors declare that they have no conflicts of interest.

Funding

No external funding.

References

1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020 Mar 11. pii: S0140-6736(20)30566-3. doi: 10.1016/S0140-6736(20)30566-3. [Epub ahead of print].
2. Cheng ZJ, Shan J. 2019 Novel coronavirus: where we are and what we know. *Infection* 2020 Feb 18. doi: 10.1007/s15010-020-01401-y. [Epub ahead of print].
3. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. *JAMA* 2020 Feb 24. doi: 10.1001/jama.2020.2648. [Epub ahead of print].
4. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. *N Engl J Med* 2020;382:929-36. doi: 10.1056/NEJMoa2001191.
5. Lee PI, Hu YL, Chen PY, Huang YC, Hsueh PR. Are children less susceptible to COVID-19? *J Microbiol Immunol Infect* 2020 Feb 25. pii:

- 427 S1684-1182(20)30039-6. doi: 10.1016/j.jmii.2020.02.011. [Epub ahead of
428 print].
- 429 6. Huang WH, Teng LC, Yeh TK, Chen YJ, Lo WJ, Wu MJ, et al. 2019 novel
430 coronavirus disease (COVID-19) in Taiwan: Reports of two cases from
431 Wuhan, China. *J Microbiol Immunol Infect* 2020 Feb 19. pii:
432 S1684-1182(20)30037-2. doi: 10.1016/j.jmii.2020.02.009. [Epub ahead of
433 print].
- 434 7. Burke RM, Midgley CM, Dratch A, Fenstersheib M, Haupt T, Holshue M, et
435 al. Active monitoring of persons exposed to patients with confirmed
436 COVID-19 - United States, January-February 2020. *MMWR Morb Mortal*
437 *Wkly Rep* 2020;**69**:245-6.
- 438 8. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-lymphocyte
439 ratio predicts severe illness patients with 2019 novel coronavirus in the
440 early stage. *medRxiv* 2020. doi:
441 <https://doi.org/10.1101/2020.02.10.20021584>.
- 442 9. Cao Q, Chen YC, Chen CL, Chiu CH. SARS-CoV-2 infection in children:
443 Transmission dynamics and clinical characteristics. *J Formos Med Assoc*
444 2020;**119**:670-3.
- 445 10. Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, et al. Clinical

- 446 progression and viral load in a community outbreak of
 447 coronavirus-associated SARS pneumonia: a prospective study. *Lancet*
 448 2003;**361**:1767-72. doi: 10.1016/s0140-6736(03)13412-5.
- 449 11. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and
 450 clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia
 451 in Wuhan, China: a descriptive study. *Lancet* 2020;**395**:507-13.
- 452 12. Hofmann H, Pyrc K, van der Hoek L, Geier M, Berkhout B, Pöhlmann S.
 453 Human coronavirus NL63 employs the severe acute respiratory syndrome
 454 coronavirus receptor for cellular entry. *Proc Natl Acad Sci USA*
 455 2005;**102**:7988-93.
- 456 13. Lee KH, Yoo SG, Cho Y, Kwon DE, La Y, Han SH, et al. Characteristics of
 457 community-acquired respiratory viruses infections except seasonal
 458 influenza in transplant recipients and non-transplant critically ill patients. *J*
 459 *Microbiol Immunol Infect* 2019 Jun 19. pii: S1684-1182(18)30233-0. doi:
 460 10.1016/j.jmii.2019.05.007.
- 461 14. Lee PI, Hsueh PR. Emerging threats from zoonotic coronaviruses-from
 462 SARS and MERS to 2019-nCoV. *J Microbiol Immunol Infect* 2020 Feb 4.
 463 pii: S1684-1182(20)30011-6. doi: 10.1016/j.jmii.2020.02.001.
- 464 15. To KW, Tsang TY, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal

- 465 profiles of viral load in posterior oropharyngeal saliva samples and serum
 466 antibody responses during infection by SARS-CoV-2: an observational
 467 cohort study. *Lancet Infect Dis* 2020 Mar 23.
 468 doi:[https://doi.org/10.1016/S1473-3099\(20\)30196-1](https://doi.org/10.1016/S1473-3099(20)30196-1).
- 469 16. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus
 470 (2019-nCoV). *Nat Rev Drug Discov* 2020;**19**:149-50. doi:
 471 [10.1038/d41573-020-00016-0](https://doi.org/10.1038/d41573-020-00016-0).
- 472 17. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al.
 473 Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is
 474 mediated by the viral polymerase and the proofreading exoribonuclease.
 475 *mBio* 2018;**9**. pii: e00221-18. doi: [10.1128/mBio.00221-18](https://doi.org/10.1128/mBio.00221-18).
- 476 18. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case
 477 JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and
 478 zoonotic coronaviruses. *Sci Transl Med* 2017;**9**. pii: eaal3653. doi:
 479 [10.1126/scitranslmed.aal3653](https://doi.org/10.1126/scitranslmed.aal3653).
- 480 19. Martinez MA. Compounds with therapeutic potential against novel
 481 respiratory 2019 coronavirus. *Antimicrob Agents Chemother* 2020 Mar 9.
 482 pii: AAC.00399-20. doi: [10.1128/AAC.00399-20](https://doi.org/10.1128/AAC.00399-20).
- 483 20. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al.

- 484 Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in
 485 rhesus monkeys. *Nature* 2016;**531**:381-5.
- 486 21. Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi
 487 D, et al. A randomized, controlled trial of Ebola virus disease therapeutics.
 488 *N Engl J Med* 2019;**381**:2293-303.
- 489 22. Medrxiv News, from: <https://times.hinet.net/mobile/news/22831665>; data
 490 accessed 20 March, 2020.
- 491 23. Brown AJ, Won JJ, Graham RL, Dinnon KH 3rd, Sims AC, Feng JY, et al.
 492 Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic
 493 deltacoronaviruses with a highly divergent RNA dependent RNA
 494 polymerase. *Antiviral Res* 2019;**169**:104541.
- 495 24. Ko WC, Rolain JM, Lee NY, Chen PL, Huang CT, Lee PI, et al. Arguments
 496 in favour of remdesivir for treating SARS-CoV-2 infections. *Int J*
 497 *Antimicrob Agents* 2020 Mar 6:105933. doi:
 498 10.1016/j.ijantimicag.2020.105933.
- 499 25. de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, et al.
 500 Prophylactic and therapeutic remdesivir (GS-5734) treatment in the
 501 rhesus macaque model of MERS-CoV infection. *Proc Natl Acad Sci USA*
 502 2020 Feb 13. pii: 201922083. doi: 10.1073/pnas.1922083117.

- 503 26. Wang Y, Fan G, Salam A, Horby P, Hayden FG, Chen C, et al.
504 Comparative effectiveness of combined favipiravir and oseltamivir therapy
505 versus oseltamivir monotherapy in critically ill patients with influenza virus
506 infection. *J Infect Dis* 2019 Dec 11. pii: jiz656. doi: 10.1093/infdis/jiz656.
- 507 27. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum
508 inhibitor of viral RNA polymerase. *Proc Jpn Acad Ser B Phys Biol Sci*
509 2017;**93**:449-63.
- 510 28. XinhuaNet. Favipiravir shows good clinical efficacy in treating COVID-19:
511 official. From:
512 http://www.xinhuanet.com/english/2020-03/17/c_138888226.htm
513 (accessed 19 March, 2020).
- 514 29. Chan JFW, Yao Y, Yeung ML, Deng W, Bao L, Jia L, et al. Treatment with
515 lopinavir/ritonavir or interferon- β 1b improves outcome of MERS-CoV
516 infection in a nonhuman primate model of common marmoset. *J Infect Dis*
517 2015;**212**:1904-13.
- 518 30. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug
519 discovery and therapeutic options. *Nat Rev Drug Discov* 2016;**15**:327-47.
- 520 31. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al.
521 Comparative therapeutic efficacy of remdesivir and combination lopinavir,

- 522 ritonavir, and interferon beta against MERS-CoV. *Nat Commun*
 523 2020;**11**:222. doi: 10.1038/s41467-019-13940-6.
- 524 32. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of
 525 lopinavir-ritonavir in adults hospitalized with severe COVID-19. *N Engl J*
 526 *Med* 2020 Mar 18. doi: 10.1056/NEJMoa2001282.
- 527 33. Baden LR, Rubin EJ. COVID-19 - The search for effective therapy. *N Engl*
 528 *J Med* 2020 Mar 18. doi: 10.1056/NEJMe2005477.
- 529 34. News. Abidol and darunavir can effectively inhibit coronavirus
 530 <http://www.sd.chinanews.com/2/2020/0205/70145.html> (accessed
 531 February 21, 2020) (in Chinese).
- 532 35. Falzarano D, de Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP,
 533 et al. Treatment with interferon- α 2b and ribavirin improves outcome in
 534 MERS-CoV-infected rhesus macaques. *Nat Med* 2013;**19**:1313-7.
- 535 36. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role
 536 of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical
 537 findings. *Thorax* 2004;**59**:252-6.
- 538 37. Yan Y, Zou Z, Sun Y, Li X, Xu KF, Wei Y, et al. Anti-malaria drug
 539 chloroquine is highly effective in treating avian influenza A H₅N₁ virus
 540 infection in an animal model. *Cell Res* 2013;**23**:300-2.

- 541 38. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek
542 TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection
543 and spread. *Virology* 2005;**2**:69. doi: 10.1186/1743-422X-2-69.
- 544 39. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and
545 chloroquine effectively inhibit the recently emerged novel coronavirus
546 (2019-nCoV) in vitro. *Cell Res* 2020;**30**:269-71.
- 547 40. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic
548 review on the efficacy and safety of chloroquine for the treatment of
549 COVID-19. *J Crit Care* 2020 Mar 10. pii: S0883-9441(20)30390-7. doi:
550 10.1016/j.jcrc.2020.03.005.
- 551 41. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity
552 and projection of optimized dosing design of hydroxychloroquine for the
553 treatment of severe acute respiratory syndrome coronavirus 2
554 (SARS-CoV-2). *Clin Infect Dis* 2020 Mar 9. pii: ciaa237. doi:
555 10.1093/cid/ciaa237.
- 556 42. Gautret P, Lagier J, Parola P, Hoang VT, Meddeb L, Mailhe M, et al.
557 Hydroxychloroquine and azithromycin as a treatment of COVID-19:
558 results of an open-label non-randomized clinical trial. *Int J Antimicrob*
559 *Agents* 2020 Mar 17. doi : 10.1016/j.ijantimicag.2020.105949.

- 560 43. Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN, Green CE,
561 et al. Evaluation of Ebola virus inhibitors for drug repurposing. *ACS Infect*
562 *Dis* 2015;**1**:317-26.
- 563 44. Bacharier LB, Guilbert TW, Mauger DT, Boehmer S, Beigelman A,
564 Fitzpatrick AM, et al. Early administration of azithromycin and prevention
565 of severe lower respiratory tract illnesses in preschool children with a
566 history of such illnesses: A randomized clinical trial. *JAMA*
567 2015;**314**:2034-44.
- 568 45. Wang Y, Cui R, Li G, Gao Q, Yuan S, Altmeyer R, et al. Teicoplanin inhibits
569 Ebola pseudovirus infection in cell culture. *Antiviral Res* 2016;**125**:1-7. doi:
570 10.1016/j.antiviral.2015.11.003.
- 571 46. Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C, et al. Glycopeptide
572 antibiotics potently inhibit cathepsin L in the late endosome/lysosome and
573 block the entry of Ebola virus, Middle East respiratory syndrome
574 coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome
575 coronavirus (SARS-CoV). *J Biol Chem* 2016;**291**:9218-32.
- 576 47. Baron SA, Devaux C, Colson P, Raoult D, Rolain JM. Teicoplanin: an
577 alternative drug for the treatment of coronavirus COVID-19? *Int J*
578 *Antimicrob Agents* 2020 Mar 13:105944. doi:

- 579 10.1016/j.ijantimicag.2020.105944.
- 580 48. Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, et al.
- 581 Advances in respiratory virus therapeutics - A meeting report from the 6th
- 582 isirv Antiviral Group conference. *Antiviral Res* 2019;**167**:45-67. doi:
- 583 10.1016/j.antiviral.2019.04.006.
- 584 49. Beigel JH, Voell J, Kumar P, Raviprakash K, Wu H, Jiao JA, Sullivan E, et
- 585 al. Safety and tolerability of a novel, polyclonal human anti-MERS
- 586 coronavirus antibody produced from transchromosomic cattle: a phase 1
- 587 randomised, double-blind, single-dose-escalation study. *Lancet Infect Dis*
- 588 2018;**18**:410-8.
- 589 50. Cockrell AS, Yount BL, Scobey T, Jensen K, Douglas M, Beall A, et al. A
- 590 mouse model for MERS coronavirus-induced acute respiratory distress
- 591 syndrome. *Nat Microbiol* 2016;**2**:16226.
- 592 51. Glowacka I, Bertram S, Müller MA, Allen P, Soilleux E, Pfefferle S, et al.
- 593 Evidence that TMPRSS2 activates the severe acute respiratory syndrome
- 594 coronavirus spike protein for membrane fusion and reduces viral control
- 595 by the humoral immune response. *J Virol* 2011;**85**:4122-34.
- 596 52. Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S.
- 597 Simultaneous treatment of human bronchial epithelial cells with serine and

- 598 cysteine protease inhibitors prevents severe acute respiratory syndrome
599 coronavirus entry. *J Virol* 2012;**86**:6537-45.
- 600 53. Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R Jr, Nunneley JW, et al.
601 Protease inhibitors targeting coronavirus and filovirus entry. *Antiviral Res*
602 2015;**116**:76-84.
- 603 54. News. FDA approves COVACTA trial for RA drug Actemra in COVID-19
604 patients. From:
605 [https://www.pharmaceutical-business-review.com/news/covacta-trial-](https://www.pharmaceutical-business-review.com/news/covacta-trial-actemra-covid-19/)
606 actemra-covid-19/. Accessed 28 March, 2020.
- 607 55. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential
608 therapy for COVID-19. *Lancet Infect Dis* 2020;S1473-3099(20)30141-9.
- 609 56. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5
610 critically ill patients with COVID-19 with convalescent plasma. *JAMA* 2020
611 Mar 27. doi:10.1001/jama.2020.4783.
- 612 57. Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: old tricks for
613 new challenges. *Crit Care* 2020;**24**:91.
- 614 58. Luo H, Tang QL, Shang YX, Liang SB, Yang M, Robinson N, et al. Can
615 Chinese medicine be used for prevention of corona virus disease 2019
616 (COVID-19)? A review of historical classics, research evidence and

- 617 current prevention programs. *Chin J Integr Med* 2020 Feb 22. doi:
618 10.1007/s11655-020-3192-6.
- 619 59. Lai CC, Wang CY, Hsueh PR. Co-infection among patients with COVID-19
620 (manuscript submitted).
- 621 60. Chou CC, Shen CF, Chen SJ, Chen HM, Wang YC, Chang WS, et al.
622 Recommendations and guidelines for the treatment of pneumonia in
623 Taiwan. *J Microbiol Immunol Infect* 2019;**52**:172-99. doi:
624 10.1016/j.jmii.2018.11.004.
- 625 61. Jean SS, Chang YC, Lin WC, Lee WS, Hsueh PR, Hsu CW. Epidemiology,
626 treatment, and prevention of nosocomial bacterial pneumonia. *J Clin Med*
627 2020;**9**:275. doi: 10.3390/jcm9010275.
- 628 62. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and
629 outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan,
630 China: A single-centered, retrospective, observational study. *Lancet*
631 *Respir Med* 2020 Feb 24. doi: 10.1016/S2213-2600(20)30079-5.
- 632 63. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical
633 characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020
634 Feb 28. doi: 10.1056/NEJMoa2002032.
- 635 64. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and

- 636 diabetes mellitus at increased risk for COVID-19 infection? *Lancet Respir*
637 *Med* 2020 Mar 11. doi: 10.1016/S2213-2600(20)30116-8.
- 638 65. FDA News. No scientific evidence that NSAID use worsens COVID-19
639 symptoms. From:
640 [https://www.drugtopics.com/latest/fda-no-scientific-evidence-nsaid-](https://www.drugtopics.com/latest/fda-no-scientific-evidence-nsaid-use-worsens-covid-19-symptoms)
641 [use-worsens-covid-19-symptoms](https://www.drugtopics.com/latest/fda-no-scientific-evidence-nsaid-use-worsens-covid-19-symptoms) (accessed 24 March, 2020).
- 642 66. Day M. COVID-19: Ibuprofen should not be used for managing symptoms,
643 say doctors and scientists. *BMJ* 368, m1086. 2020 Mar 17. doi:
644 10.1136/bmj.m1086.
- 645 67. Society of Critical Care Medicine. COVID-19 Guidelines. From:
646 <https://www.sccm.org/SurvivingSepsisCampaign/Guidelines/COVID-19>.
- 647 68. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated
648 with acute respiratory distress syndrome and death in patients with
649 coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med*
650 2020 Mar 13. doi: 10.1001/jamainternmed.2020.0994.
- 651 69. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z, et al. Anticoagulant
652 treatment is associated with decreased mortality in severe coronavirus
653 disease 2019 patients with coagulopathy. *J Thromb Haemost* 2020 March
654 27. doi.org/10.1111/jth.14817.

70. Wösten-van Asperen RM, Bos AP, Bem RA, Dierdorp BS, Dekker T, van
Goor H, et al. Imbalance between pulmonary angiotensin-converting
enzyme and angiotensin-converting enzyme 2 activity in acute respiratory
distress syndrome. *Pediatr Crit Care Med* 2013;**14**:e438-41. doi:
10.1097/PCC.0b013e3182a55735.
71. Fedson DS. Treating the host response to emerging virus diseases:
lessons learned from sepsis, pneumonia, influenza and Ebola. *Ann Transl
Med* 2016;**4**:421. doi: 10.21037/atm.2016.11.03.
72. Fedson DS, Opal SM, Rordam OM. Hiding in plain sight: an approach to
treating patients with severe COVID-19 infection. *mBio* 2020;**11**. doi:
10.1128/mBio.00398-20.

667 **Table 1** Mechanisms of action and targets of potential treatment agents for SARS-CoV-2 infections

Mechanism of action and targets	Drugs
Inhibition of the RNA-dependent RNA polymerase	Remdesivir Favipiravir Ribavirin
Inhibition of spike protein on SARS-CoV-2 (non-endosomal pathway)	TMPRSS2 inhibitor (camostat mesylate)
Inhibition of endosomal acidification (early endosomal pathway)	Chloroquine, hydroxychloroquine (azithromycin is reported to greatly enhance the anti-SARS-CoV-2 activity of hydroxychloroquine)
Inhibition of viral exocytosis	Interferon- α 2a Interferon- β 1b
Inhibition of papain-like protease and 3C-like protease	Lopinavir/ritonavir
Inhibition of cathepsin L and cathepsin B in host cells (late endosomal pathway)	Teicoplanin (other glycopeptides including dalbavancin, oritavancin, and telavancin)
Enhancement of the anti-SARS-CoV-2 activity of hydroxychloroquine	Azithromycin

668